Armis Named ‘Outperformer’ and ‘Leader’ in GigaOm Radar Report for Operational Technology Security for Second Consecutive Year
24.6.2024 18:15:00 EEST | Business Wire | Press release
Armis, the asset intelligence cybersecurity company, today announced that it has been named a Leader and Outperformer in the 2024 GigaOm Radar Report for Operational Technology (OT) Security. This is the second year running is recognized as a Leader in the field of OT Security, cementing its status as a mature platform solution providing proactive end-to-end security for cross-vertical organizations looking for a cohesive approach to OT Security management.
Armis scored multiple 5/5 perfect scores showcasing Armis’ customer-centric vision to deliver OT security built on deep asset context, proactive threat intelligence and total vulnerability management. From cost and ease of use to scalability and flexibility and certification, Armis was recognized for being built for smooth deployment in OT environments.
“The on-going development of the Armis Centrix™ platform has enabled us to offer complete end to end OT security management from complete visibility, vulnerability remediation and management through to advanced AI threat detection,” said Yevgeny Dibrov, CEO and Co-founder of Armis. “I am grateful to GigaOm for recognizing, not just our leadership position, but also awarding us 'Outperformer status', praising the developments we have made this past year.”
The GigaOm Radar is a thoroughly comprehensive technology analysis of OT security solutions on the market today, focusing on the latest innovation and critical capabilities that customers need to protect their entire environment. It also benchmarks current solutions and is able to effectively track how OT/ICS security has evolved in order to stay ahead of modern threat actors and attack vectors.
“Armis has excelled in rapidly advancing its technological offerings and has notably enhanced its threat detection capabilities over the past year, pushing the boundaries of innovation in OT security,” said Chris Ray, Research Analyst at GigaOm. “Armis is positioned as a Platform Play because it offers an extensive and integrated security platform capable of addressing multiple OT security concerns, making it well-suited for organizations seeking comprehensive solutions. It is classified as Innovative due to its aggressive approach in introducing new features and capabilities, which highlights its commitment to staying ahead in technology advancements. Armis has achieved Leader status thanks to its effective market penetration and the robustness of its security solutions.”
Within the GigaOm Radar for OT Security, Armis Centrix™ is recognized for:
- Asset Discovery - Armis' automated asset discovery feature received a 5/5 score for surpassing traditional methods by incorporating passive network discovery, active asset querying techniques, integration-based approaches, and asset profiling. This thorough strategy ensures precise identification of all devices, managed or unmanaged, granting organizations a complete view of their network landscape.
- Dynamic Network Segmentation - Additionally, Armis received a 5/5 score for its dynamic network segmentation, utilizing knowledge of VLANs, subnets, and wireless networks to create device segments as the dynamic attack surface requires, and provide insights into architectural changes for more secure environments.
- Managing Complex, Converged Environments - Armis demonstrated proficiency in managing diverse environments, including the OT, IT, IoT, and medical sectors. Armis Centrix™ showcased strong adherence to industry standards and regulatory requirements, scoring a 5/5 for business certification criterion thus instilling trust and confidence in its customers. Notable certifications include FedRAMP, DoD Impact Level 4, ISO 27001, ISO 28018, and SOC 2 type 2.
- Next-Generation AI Threat Detection - With the addition of actionable threat intelligence capabilities this year Armis displayed huge growth in AI technologies for threat detection. Scoring a 5/5, Armis was applauded for using AI to identify attacks still in the formulation stage as well as pinpointing anomalous behavior, unusual activities, malicious code, and other threats in real time. Armis integrates with SIEM, SOAR, XDR, and ASM solutions, ensuring comprehensive coverage and visibility across the entire attack surface.
- Integration with IT security systems - Ensuring coordinated security efforts across both IT and OT environments. This convergence enhances the overall cybersecurity posture of an organization, addressing complex, multifaceted threats that span the IT-OT divide.
- Providing visualization of OT asset relationships - Offering best-in-class dashboards and Purdue modeling to represent how OT assets connect and interact within an organization's network. This visibility is essential for understanding potential pathways of cyber threats and optimizing security responses.
“Armis offers a comprehensive suite of security features well-suited for SMBs, large enterprises, and public sector organizations,” continued Ray. “Leaders like Armis demonstrate robust platform capabilities with wide-reaching security features, making them stalwarts in the industry.”
The 2024 GigaOm Radar Report is a valuable resource for organizations aiming to enhance their OT security posture. It offers a thorough overview of the OT security market and highlights the leading vendors in the space. To learn more, read the Armis blog highlighting key findings from this year’s report here.
About Armis
Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization’s cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets – from the ground to the cloud. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240624790874/en/
Contacts
Rebecca Cradick
Senior Director, Global Communications
Armis
pr@armis.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom